Thus, molecular parameters have been used to more accurately classify and predict the prognosis of the various glioma types [3], such as isocitrate dehydrogenase 1 prime 2 (IDH1/2) mutation, ATRX mutation, glioma-CpG island methylation phenotype, O6-methylguanine-DNA methyltransferase methylation, and chromosome arm 1p19q codeletion. The gene discussed is MGMT; the disease is central nervous system cancer.